PMID- 38504387
OWN - NLM
STAT- MEDLINE
DCOM- 20240409
LR  - 20240507
IS  - 1096-8652 (Electronic)
IS  - 0361-8609 (Linking)
VI  - 99
IP  - 5
DP  - 2024 May
TI  - Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients 
      and/or patients with poor ECOG performance status with relapsed or refractory 
      large B-cell lymphoma after 2 or more lines of prior therapy.
PG  - 880-889
LID - 10.1002/ajh.27283 [doi]
AB  - Axicabtagene ciloleucel (axi-cel) in trials has demonstrated favorable efficacy 
      compared with historical controls after >/=2 lines of therapy for the treatment of 
      relapsed or refractory (R/R) large B cell lymphoma (LBCL). Herein, we compared 
      the real-world effectiveness of axi-cel with efficacy and effectiveness of 
      chemoimmunotherapy (CIT) in patients aged >/=65 years and patients with Eastern 
      Cooperative Oncology Group performance status (ECOG PS) of 2. A total of 1146 
      patients treated with commercial axi-cel for R/R LBCL with >/=2 lines of prior 
      therapy were included from the Center for International Blood and Marrow 
      Transplantation Research prospective observational study, and 469 patients 
      treated with CIT for R/R LBCL after >/=2 lines of prior therapy were included from 
      SCHOLAR-1 (an international, multicohort, retrospective study). After propensity 
      score matching, at a median follow-up of 24 months for patients receiving axi-cel 
      and 60 months for patients receiving CIT, 12-month overall survival rates were 
      62% and 28%, respectively (hazard ratio, 0.30 [95% CI, 0.24-0.37]). Objective 
      response rate (ORR) was 76% (complete response [CR] rate 58%) in patients 
      receiving axi-cel versus 28% (CR rate 16%) for those receiving CIT. A 57% 
      difference in ORR (55% difference in CR rate) favoring axi-cel over CIT was 
      observed among patients aged >/=65 years. Increased magnitude of benefit in 
      response rates for axi-cel versus CIT was also observed among patients with ECOG 
      PS = 2. These findings further support the broader use of axi-cel in older 
      patients and patients with ECOG PS = 2 with R/R LBCL.
CI  - (c) 2024 The Authors. American Journal of Hematology published by Wiley Periodicals 
      LLC.
FAU - Lunning, Matthew A
AU  - Lunning MA
AUID- ORCID: 0000-0002-2761-7612
AD  - University of Nebraska, Omaha, Nebraska, USA.
FAU - Wang, Hai-Lin
AU  - Wang HL
AD  - Kite, A Gilead Company, Santa Monica, California, USA.
FAU - Hu, Zhen-Huan
AU  - Hu ZH
AD  - Kite, A Gilead Company, Santa Monica, California, USA.
FAU - Locke, Frederick L
AU  - Locke FL
AD  - Moffitt Cancer Center, Tampa, Florida, USA.
FAU - Siddiqi, Tanya
AU  - Siddiqi T
AD  - City of Hope National Medical Center, Duarte, California, USA.
FAU - Jacobson, Caron A
AU  - Jacobson CA
AD  - Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
FAU - Ahmed, Sairah
AU  - Ahmed S
AD  - The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
FAU - Miklos, David B
AU  - Miklos DB
AD  - Stanford University School of Medicine, Stanford, California, USA.
FAU - Lin, Yi
AU  - Lin Y
AD  - Mayo Clinic, Rochester, Minnesota, USA.
FAU - Hill, Brian T
AU  - Hill BT
AD  - Cleveland Clinic Foundation, Cleveland, Ohio, USA.
FAU - Ghobadi, Armin
AU  - Ghobadi A
AD  - Washington University School of Medicine, St Louis, Missouri, USA.
FAU - Neelapu, Sattva S
AU  - Neelapu SS
AD  - The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
FAU - Westin, Jason
AU  - Westin J
AUID- ORCID: 0000-0002-1824-2337
AD  - The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
FAU - Dieyi, Chrisopher
AU  - Dieyi C
AD  - Kite, A Gilead Company, Santa Monica, California, USA.
FAU - Field, Polly
AU  - Field P
AD  - Oxford PharmaGenesis, Oxford, UK.
FAU - Miao, Harry
AU  - Miao H
AD  - Kite, A Gilead Company, Santa Monica, California, USA.
FAU - Shahani, Shilpa A
AU  - Shahani SA
AD  - Kite, A Gilead Company, Santa Monica, California, USA.
FAU - Patel, Anik
AU  - Patel A
AD  - Kite, A Gilead Company, Santa Monica, California, USA.
FAU - Spooner, Clare
AU  - Spooner C
AD  - Kite, A Gilead Company, Santa Monica, California, USA.
FAU - Fu, Christine
AU  - Fu C
AD  - Kite, A Gilead Company, Santa Monica, California, USA.
FAU - Muramoto, David
AU  - Muramoto D
AD  - Kite, A Gilead Company, Santa Monica, California, USA.
FAU - Xu, Hairong
AU  - Xu H
AD  - Kite, A Gilead Company, Santa Monica, California, USA.
FAU - Pasquini, Marcelo C
AU  - Pasquini MC
AD  - CIBMTR, Milwaukee, Wisconsin, USA.
LA  - eng
GR  - OT3HL147741/BC/NCI NIH HHS/United States
GR  - U01HL128568/BC/NCI NIH HHS/United States
GR  - HHSH250201700005C/HB/NHLBI NIH HHS/United States
GR  - HHSH250201700006C/HB/NHLBI NIH HHS/United States
GR  - HHSH250201700007C/HB/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Observational Study
DEP - 20240319
PL  - United States
TA  - Am J Hematol
JT  - American journal of hematology
JID - 7610369
RN  - U2I8T43Y7R (axicabtagene ciloleucel)
RN  - 0 (Biological Products)
RN  - 0 (Antigens, CD19)
SB  - IM
EIN - Am J Hematol. 2024 May 7;:. PMID: 38712755
MH  - Humans
MH  - Aged
MH  - Retrospective Studies
MH  - *Lymphoma, Large B-Cell, Diffuse/drug therapy
MH  - *Biological Products/therapeutic use
MH  - Pathologic Complete Response
MH  - Immunotherapy, Adoptive
MH  - Antigens, CD19
EDAT- 2024/03/20 06:45
MHDA- 2024/04/09 06:45
CRDT- 2024/03/20 00:57
PHST- 2024/01/25 00:00 [revised]
PHST- 2023/11/08 00:00 [received]
PHST- 2024/02/18 00:00 [accepted]
PHST- 2024/04/09 06:45 [medline]
PHST- 2024/03/20 06:45 [pubmed]
PHST- 2024/03/20 00:57 [entrez]
AID - 10.1002/ajh.27283 [doi]
PST - ppublish
SO  - Am J Hematol. 2024 May;99(5):880-889. doi: 10.1002/ajh.27283. Epub 2024 Mar 19.